Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil for NIV tolerance in acute hypercapnic respiratory failure
NCT02264626Unknown
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Oct 2014
- Primary completion
- Oct 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of remifentanil in Acute Hypercapnic Respiratory Failure (AHRF), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Patient-ventilator interaction at 1 hour, Matching of inspiratory timing at 1 hour and 1 more. Status: unknown.
02
Drugs
remifentanil
03
Conditions
Acute Hypercapnic Respiratory Failure (AHRF)
Beyond the preview
Go deeper on NCT02264626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264626.